Not all progestins are the same: Implications for usage

Trends in Pharmacological Sciences

Volumn 25, Issue 11, 2004, Pages 554-557

  Hapgood, Janet P ^a   Koubovec, Dominique ^a   Louw, Ann ^a   Africander, Donita ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; ESTROGEN; GESTAGEN; GLUCOCORTICOID; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETHISTERONE ENANTATE; PROGESTERONE; STEROID; TRIMEGESTONE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CONFUSION; CONTRACEPTION; DEVELOPMENTAL DISORDER; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; FETOTOXICITY; FRACTURE; GENE EXPRESSION; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNOMODULATION; INFECTION; INFECTION SENSITIVITY; LIVER TOXICITY; LONG TERM CARE; NONHUMAN; PERINATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 5644234129     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.09.005     Document Type: Short Survey

References (27)

1. Schindler, A.E. et al. (2003) Classification and pharmacology of progestins. Maturitas. 46 (Suppl.) 1, S7-S16
2. Sitruk-Ware, R.L. (2003) Hormone therapy and the cardiovascular system: the critical role of progestins. Climacteric 6 (Suppl.) 3, 21-28
3. B. Affandi Long-acting progestogens Best Practice Res. Clin. Obstet. Gynaecol. 16 2002 169 179
4. C. Stahlberg Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe Int. J. Cancer 109 2004 721 727
5. J.E. Rossouw Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial J. Am. Med. Assoc. 288 2002 321 333
6. Million women study collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
7. I. Valdivia Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women Fertil. Steril. 81 2004 617 623
8. I.S. Odmark Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins Maturitas 48 2004 137 146
9. W. Oelkers Drospirenone, a progestogen with antimineralocorticoid properties: a short review Mol. Cell. Endocrinol. 217 2004 255 261
10. J. McKenzie Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clin. Endocrinol. 59 2003 682 699
11. A.K. Ildgruben Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium Obstet. Gynecol. 102 2003 571 582
12. C.C. Wang The effect of hormonal contraception on genital tract shedding of HIV-1 AIDS 18 2004 205 209
13. C. Kaushic Progesterone increases susceptibility and decreases immune responses to genital herpes infection J. Virol. 77 2003 4558 4565
14. A.E. Gillgrass Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2 J. Virol. 77 2003 9845 9851
15. J. Kurebayashi Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2 Thyroid 13 2003 249 258
16. D. Koubovec Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells Mol. Cell. Endo. 221 2004 75 85
17. M. Elovitz, and Z. Wang Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise Am. J. Obstet. Gynecol. 190 2004 693 701
18. C. Westhoff Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraception option with proven long-term safety Contraception 68 2003 75 87
19. A.G. Nugent Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women Clin Endocrinol. 59 2003 690 698
20. F.Z. Stanczyk, and S. Roy Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids Contraception 42 1990 67 96
21. J.L. Turgeon Hormone therapy: physiological complexity belies therapeutic simplicity Science 304 2004 1269 1273
22. J. Nilsen, and R.D. Brinton Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling Proc. Natl. Acad. Sci. U. S. A. 100 2003 10506 10511
23. R.C. Winneker The preclinical biology of a new potent and selective progestin: trimegestone Steroids 86 2003 915 920
24. J.A. Kemppainen Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone Mol. Endocrinol. 13 1999 440 454
25. C.M. Bamberger Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes J. Clin. Endocrinol. Metab. 84 1999 4055 4061
26. Q. Zhao Receptor density dictates the behaviour of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression Int. Immunopharmacol. 3 2003 1803 1817
27. P. Zhang Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists Bioorg. Med. Chem. Lett. 13 2003 1313 1316